Pierre Fabre Laboratories has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use recommending approval of Braftovi (encorafenib) in combination with cetuximab and FOLFOX for the first-line treatment of adult patients with BRAF V600E-mutant metastatic colorectal cancer, marking the first targeted therapy recommended for this setting in the EU.
The CHMP opinion will now be forwarded to the European Commission, with a final marketing authorisation decision expected later in 2026. If granted, the approval would represent a label expansion for encorafenib in the EU, where the drug has previously been authorised only for previously treated BRAF V600E-mutant metastatic colorectal cancer in combination with cetuximab alone, based on data from the BEACON CRC trial.
The filing is supported by data from the Phase III BREAKWATER trial (NCT04607421), which assessed encorafenib combined with cetuximab and mFOLFOX6 against oxaliplatin-based chemotherapy with or without bevacizumab in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer. The trial met its dual primary endpoints of objective response rate and progression-free survival. Median PFS was 12.8 months in the encorafenib arm versus 7.1 months in the control arm, corresponding to a hazard ratio of 0.53 (95% CI, 0.41 to 0.68). The company also reported a 51% reduction in the risk of death compared with chemotherapy with or without bevacizumab, though full overall survival statistics were not disclosed in the press release.
BRAF V600E mutations occur in approximately 8% to 12% of metastatic colorectal cancer patients and are associated with an aggressive disease course, right-sided tumour predominance, and historically poor outcomes on standard chemotherapy. Prior to the approval of encorafenib-based regimens, median overall survival in this population on first-line chemotherapy was generally below 12 months. The BREAKWATER data, which informed a US FDA accelerated approval in December 2024 and a subsequent full traditional approval in February 2026, now underpin the European regulatory recommendation.
Encorafenib is an oral small-molecule inhibitor of mutant BRAF kinase. In colorectal cancer, BRAF inhibition alone has limited efficacy due to EGFR-mediated reactivation of the MAPK signalling pathway — a feedback mechanism that does not occur in melanoma and that drove the rational design of the encorafenib-plus-cetuximab combination. The addition of mFOLFOX6 chemotherapy to that doublet was investigated in BREAKWATER as a means of further deepening response in the first-line setting, where tumour burden and disease tempo are typically high.
The competitive context for this indication remains narrow. No other targeted agent has received regulatory approval specifically for first-line BRAF V600E-mutant metastatic colorectal cancer in the EU. In the MSI-H/dMMR subpopulation, which accounts for roughly 20 to 30% of BRAF V600E-mutant cases, immune checkpoint inhibitors including pembrolizumab are approved and represent an alternative first-line strategy, though optimal sequencing with encorafenib-based therapy in that subset remains an open clinical question. For the larger MSS/pMMR population, no immunotherapy option is currently validated, and the encorafenib triplet addresses a setting with limited alternatives.